Oncotarget: Championing for Impact of Oncology Research
One of the toughest challenges facing the fight against many diseases including cancer is availability and accessibility of information. Cancer research aimed at establishing research-based diagnostic, treatment and management procedures has spiked over the years due to the increased number of cancer-related deaths globally. Availing this information to the scientific communities and the rest of the population is an important step towards eliminating the scourge. One organization that is actively participating in the active generation and dispensation of research-based cancer related information is Oncotarget; a medical journal published weekly.
Rising Popularity Within Scientific Cycles
Established in 2010, Oncotarget’s popularity within the scientific cycles has soared over the years. Published weekly by Impact Journals under the sponsorship of Gordon Research Conference, the journal carries insightful researched articles authored by several researchers and scientists who are committed to advancing knowledge on cancer. The articles are very constructive and have contributed immensely towards advancing understanding of various aspects of cancer. As an open source weekly journal, the journal facilitates punctual access to information by removing the financial barrier that has the potential of curtailing cancer research and information dispensation. Additionally, multiple peer reviews ensure that the information presented for consumption is thoroughly vetted by qualified professionals. This has enabled the journal gain a respectable 5.008 when its impact factor is measured. The journal’s artciles have been cited over ten thousand times. Scopus/SJR currently ranks the journal as Q1, the highest distinction in ranking journals. Check the journal at SCImago Journal & Country Rank.
Another success factor is its online publication, which allows for ease of access for many research consumers globally. This is complimented by a special printed issue. Moreover, the journal uses a multidisciplinary approach as it publishes researches touching on various fields beyond cancer. Read more about Oncotarget at Bioxbio.
Editor-in-Chief: Mikhail Blagosklonny
Oncotarget’s popularity has also been drive by the highly qualified professionals who serve on its editorial board. Editorial board is comprised of individuals with a strong background in biology, medicine, cell and molecular biology, oncology and scientific research. They also have years of experience in their various fields. The journal’s current editor-in-chief,Mikhail Blagosklonny, is a professor of oncology and research scientist who specializes in cancer treatment and therapies including anti-aging therapies.